Literature DB >> 19447367

Hypericin and 5-aminolevulinic acid-induced protoporphyrin IX induce enhanced phototoxicity in human endometrial cancer cells with non-coherent white light.

Xiaoye Schneider-Yin1, Aida Kurmanaviciene, Marion Roth, Malgorzata Roos, André Fedier, Elisabeth I Minder, Heinrich Walt.   

Abstract

BACKGROUND: The in vitro experiments described in this study were aimed at exploring a synergistic effect between 5-aminolevulinic acid (5-ALA) induced protoporphyrin IX (PpIX) and hypericin. In a previous study, enhanced phototoxicity was observed in a patient during a clinical study on 5-ALA-based photodynamic tumor localization of breast cancer. This patient ingested a hypericin containing plant extract in parallel to orally applied 5-ALA.
METHODS: Human endometrial cancer cells (HEC-1A) were treated with 0.5mM of 5-ALA and 60 nM of hypericin, either separately or combined. Colony formation was assessed after illumination of the cells with both red (635 nm) and white light (400-800 nm) at a dose of 2.5 J/cm(2). Porphyrin metabolites were quantified by HPLC in cells treated with photosensitizers without subsequent illumination.
RESULTS: After white light illumination, cells treated with a combination of 5-ALA and hypericin had a significant reduction in colony formation compared with cells treated with 5-ALA only. No significantly enhanced toxicity was found with red light and the 5-ALA plus hypericin combination. In addition, cells treated with both 5-ALA and hypericin tended to produce more PpIX than cells treated with 5-ALA only.
CONCLUSIONS: This study demonstrated that treatment of endometrial cancer cells with both 5-ALA and hypericin followed by illumination with white light induced a significantly higher phototoxicity as revealed by colony formation. This setting which generated an in vitro effect similar to the patient's situation, might be applied in the future as an affordable and effective photodynamic therapy (PDT) modality.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19447367     DOI: 10.1016/j.pdpdt.2009.02.001

Source DB:  PubMed          Journal:  Photodiagnosis Photodyn Ther        ISSN: 1572-1000            Impact factor:   3.631


  7 in total

1.  Growth inhibition of malignant glioblastoma by DING protein.

Authors:  Markus J Bookland; Nune Darbinian; Michael Weaver; Shohreh Amini; Kamel Khalili
Journal:  J Neurooncol       Date:  2011-11-04       Impact factor: 4.130

Review 2.  The role of photodynamic therapy in overcoming cancer drug resistance.

Authors:  Bryan Q Spring; Imran Rizvi; Nan Xu; Tayyaba Hasan
Journal:  Photochem Photobiol Sci       Date:  2015-04-09       Impact factor: 3.982

3.  A Combination of Visudyne and a Lipid-anchored Liposomal Formulation of Benzoporphyrin Derivative Enhances Photodynamic Therapy Efficacy in a 3D Model for Ovarian Cancer.

Authors:  Imran Rizvi; Shubhankar Nath; Girgis Obaid; Mustafa Kemal Ruhi; Kaitlin Moore; Shazia Bano; David Kessel; Tayyaba Hasan
Journal:  Photochem Photobiol       Date:  2019-01-07       Impact factor: 3.421

Review 4.  Applications of Photodynamic Therapy in Endometrial Diseases.

Authors:  Gabriela Correia-Barros; Beatriz Serambeque; Maria João Carvalho; Carlos Miguel Marto; Marta Pineiro; Teresa M V D Pinho E Melo; Maria Filomena Botelho; Mafalda Laranjo
Journal:  Bioengineering (Basel)       Date:  2022-05-23

Review 5.  Hypericins as potential leads for new therapeutics.

Authors:  Anastasia Karioti; Anna Rita Bilia
Journal:  Int J Mol Sci       Date:  2010-02-04       Impact factor: 5.923

6.  Photodynamic Vaccination of BALB/c Mice for Prophylaxis of Cutaneous Leishmaniasis Caused by Leishmania amazonensis.

Authors:  Sayonara M Viana; Fabiana S Celes; Laura Ramirez; Bala Kolli; Dennis K P Ng; Kwang P Chang; Camila I de Oliveira
Journal:  Front Microbiol       Date:  2018-02-06       Impact factor: 5.640

7.  Two combined photosensitizers: a goal for more effective photodynamic therapy of cancer.

Authors:  P Acedo; J C Stockert; M Cañete; A Villanueva
Journal:  Cell Death Dis       Date:  2014-03-13       Impact factor: 8.469

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.